HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia.

AbstractBACKGROUND:
Emerging evidence indicates that nod-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome-induced inflammation plays a crucial role in the pathogenesis of Parkinson's disease (PD). Thus, inhibition of NLRP3 inflammasome activation may offer a therapeutic benefit in the treatment of PD. Tenuigenin, a major active component of Polygala tenuifolia, has been shown to have potential anti-inflammatory activity, but the underlying mechanisms remain obscure.
METHODS:
In the present study, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD was established to explore the effect of tenuigenin on dopaminergic neurons in substantia nigra. We next activated NLRP3 inflammasome in both BV2 microglia cells and adult mice to investigate the mechanisms for the neuroprotective effect of tenuigenin.
RESULTS:
We demonstrated that treatment with tenuigenin increased striatal dopaminergic levels and improved motor impairment induced by MPTP. Also, tenuigenin significantly ameliorated the degeneration of dopaminergic neurons and inhibited NLRP3 inflammasome activation in substantia nigra of MPTP mouse model. We further found that tenuigenin reduced intracellular reactive oxygen species (ROS) production and suppressed NLRP3 inflammasome activation, subsequent caspase-1 cleavage, and interleukin-1β secretion in BV2 microglia cells. These data indicate that tenuigenin inhibits the activation of NLRP3 inflammasome via downregulating ROS. Correspondingly, in vivo data showed that tenuigenin attenuates microglia activation induced by lipopolysaccharide (LPS) in substantia nigra via suppressing NLRP3 inflammasome.
CONCLUSIONS:
Our findings reveal that tenuigenin protects dopaminergic neurons from inflammation partly through inhibition of NLRP3 inflammasome activation in microglia, and suggest the promising clinical use of tenuigenin for PD therapy.
AuthorsZheng Fan, Zhigang Liang, Hui Yang, Yuting Pan, Yan Zheng, Xiaomin Wang
JournalJournal of neuroinflammation (J Neuroinflammation) Vol. 14 Issue 1 Pg. 256 (Dec 20 2017) ISSN: 1742-2094 [Electronic] England
PMID29262843 (Publication Type: Journal Article)
Chemical References
  • Drugs, Chinese Herbal
  • Interleukin-1beta
  • Lipopolysaccharides
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Neuroprotective Agents
  • Nlrp3 protein, mouse
  • tenuigenin
  • Adenosine Triphosphate
Topics
  • Adenosine Triphosphate (pharmacology)
  • Animals
  • Cell Line, Transformed
  • Corpus Striatum (drug effects, metabolism, pathology)
  • Disease Models, Animal
  • Dopaminergic Neurons (drug effects)
  • Drugs, Chinese Herbal (chemistry, therapeutic use)
  • Exploratory Behavior (drug effects)
  • Inflammation (drug therapy, etiology)
  • Interleukin-1beta (metabolism)
  • Lipopolysaccharides (toxicity)
  • MPTP Poisoning (drug therapy, pathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Microglia (drug effects, metabolism)
  • Motor Activity (drug effects)
  • NLR Family, Pyrin Domain-Containing 3 Protein (metabolism)
  • Neuroprotective Agents (chemistry, therapeutic use)
  • Substantia Nigra (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: